The Observation On The Clinical Effect Of Shengyangyiweitang On Spleen And Kidney Deficiency, Dampness Intrinsic Patients Of CKD3-4 Stage

Objective:To observe the clinical effect of Shengyangyiweitang on Scr, BUN, UA, eGFR, PRO, BLD, TC, TG, HDL,LDL, ApoA1,Apo-b of patients with chronic kidney disease of spleen and kidney deficiency, dampness intrinsic in 3-4 stage, thereby further evaluate the clinical application potential of Shengyangyiweitang to patients with chronic kidney disease of spleen and kidney deficiency, dampness intrinsic in 3-4 stage.Methodology:This study has chosen 60 cases of inpatients and outpatients with chronic kidney disease of spleen and kidney deficiency, dampness intrinsic in 3-4 stage as subjects. The subjects were divided randomly into experimental group and control group, with 30 cases in each. Patients in the control group were treated by conventional western medicines, while their counterparts in the experimental group received Shengyangyiweitang twice a day as an addition to the above said treatment. The experimental process lasted for 3 months. Thereafter two groups of patients before and after treatment were observed for clinical curative effect, Chinese medical symptom improvement, and changes of kidney (Scr, BUN, UA, eGFR), kidney damage(PRO, BLD) and blood lipids metabolism(TC, TG, HDL,LDL Apo-al,Apo-b).Results:(1)The clinical efficacy in the experimental group (patients have been taking Shengyangyiweitang) was 86.21%, materially higher than that (63.30%) of the control group (P<0.05); Moreover, the experimental group is better in improving the TCM syndrome languid, inappetence, soreness and weakness of waist and knees, limbs heavy, diarrhea than that in the control group (P<0.05);(2) After 3 months' treatment, the experimental group yielded better results in reducing Scr?BUN level and eGFR improvement than that of the control group, and the differences between the two groups are statistically significant (P<0.05); (3)Compared with the control group, there was a statistically significant difference in the 24 hours urinary protein quantitative reduction from the experimental group(P<0.01), which was superior as compared to the control group; (4) After 3 months' treatment, blood lipids metabolism including TC, TG, LDL, Apo-al, Apo-b were decreased and HDL has been improved in both groups, and the experimental group showed better result than that of the control group, also, a statistical difference (P<0.05) was observed.Conclusion:Shengyangyiweitang is able to improve clinical symptoms of patients with chronic kidney disease of spleen and kidney deficiency, dampness intrinsic in 3-4 stage; Also, it can reduce their serum Scr?BUN level and improve eGFR; it does significantly reduce patients'24 hours urinary protein quantitative level; Furthermore, Shengyangyiweitang has material efficacy of improving the chronic kidney disease of spleen and kidney deficiency,dampness intrinsic in 3-4 stage patients' blood lipids metabolism level.